139 related articles for article (PubMed ID: 27488901)
1. Particle Formation and Aggregation of a Therapeutic Protein in Nanobubble Suspensions.
Snell JR; Zhou C; Carpenter JF; Randolph TW
J Pharm Sci; 2016 Oct; 105(10):3057-3063. PubMed ID: 27488901
[TBL] [Abstract][Full Text] [Related]
2. Nanobubbles in Reconstituted Lyophilized Formulations: Interaction With Proteins and Mechanism of Formation.
Snell JR; Kumar NSK; Suryanarayanan R; Randolph TW
J Pharm Sci; 2020 Jan; 109(1):284-292. PubMed ID: 31095959
[TBL] [Abstract][Full Text] [Related]
3. Formation of Stable Nanobubbles on Reconstituting Lyophilized Formulations Containing Trehalose.
Zhou C; Cleland D; Snell J; Qi W; Randolph TW; Carpenter JF
J Pharm Sci; 2016 Jul; 105(7):2249-53. PubMed ID: 27287517
[TBL] [Abstract][Full Text] [Related]
4. Effects of benzyl alcohol on aggregation of recombinant human interleukin-1-receptor antagonist in reconstituted lyophilized formulations.
Roy S; Jung R; Kerwin BA; Randolph TW; Carpenter JF
J Pharm Sci; 2005 Feb; 94(2):382-96. PubMed ID: 15614819
[TBL] [Abstract][Full Text] [Related]
5. Protein-protein interactions controlling interfacial aggregation of rhIL-1ra are not described by simple colloid models.
Sorret LL; DeWinter MA; Schwartz DK; Randolph TW
Protein Sci; 2018 Jul; 27(7):1191-1204. PubMed ID: 29388282
[TBL] [Abstract][Full Text] [Related]
6. Reduced Subvisible Particle Formation in Lyophilized Intravenous Immunoglobulin Formulations Containing Polysorbate 20.
Zhou C; Qi W; Lewis EN; Randolph TW; Carpenter JF
J Pharm Sci; 2016 Aug; 105(8):2302-9. PubMed ID: 27290624
[TBL] [Abstract][Full Text] [Related]
7. High concentration formulations of recombinant human interleukin-1 receptor antagonist: II. Aggregation kinetics.
Alford JR; Kendrick BS; Carpenter JF; Randolph TW
J Pharm Sci; 2008 Aug; 97(8):3005-21. PubMed ID: 17924426
[TBL] [Abstract][Full Text] [Related]
8. Effect of benzyl alcohol on recombinant human interleukin-1 receptor antagonist structure and hydrogen-deuterium exchange.
Alford JR; Fowler AC; Wuttke DS; Kerwin BA; Latypov RF; Carpenter JF; Randolph TW
J Pharm Sci; 2011 Oct; 100(10):4215-24. PubMed ID: 21557223
[TBL] [Abstract][Full Text] [Related]
9. Temperature dependence of benzyl alcohol- and 8-anilinonaphthalene-1-sulfonate-induced aggregation of recombinant human interleukin-1 receptor antagonist.
Roy S; Katayama D; Dong A; Kerwin BA; Randolph TW; Carpenter JF
Biochemistry; 2006 Mar; 45(12):3898-911. PubMed ID: 16548517
[TBL] [Abstract][Full Text] [Related]
10. Quantitative Laser Diffraction for Quantification of Protein Aggregates: Comparison With Resonant Mass Measurement, Nanoparticle Tracking Analysis, Flow Imaging, and Light Obscuration.
Yoneda S; Niederleitner B; Wiggenhorn M; Koga H; Totoki S; Krayukhina E; Friess W; Uchiyama S
J Pharm Sci; 2019 Jan; 108(1):755-762. PubMed ID: 30237029
[TBL] [Abstract][Full Text] [Related]
11. Mechanism for benzyl alcohol-induced aggregation of recombinant human interleukin-1 receptor antagonist in aqueous solution.
Zhang Y; Roy S; Jones LS; Krishnan S; Kerwin BA; Chang BS; Manning MC; Randolph TW; Carpenter JF
J Pharm Sci; 2004 Dec; 93(12):3076-89. PubMed ID: 15514986
[TBL] [Abstract][Full Text] [Related]
12. The fine transformation between the oxidized and reduced forms of interleukin-1 receptor antagonist.
Li S; Wang L
Biologicals; 2008 Jan; 36(1):37-40. PubMed ID: 17714954
[TBL] [Abstract][Full Text] [Related]
13. Physical factors affecting the storage stability of freeze-dried interleukin-1 receptor antagonist: glass transition and protein conformation.
Chang BS; Beauvais RM; Dong A; Carpenter JF
Arch Biochem Biophys; 1996 Jul; 331(2):249-58. PubMed ID: 8660705
[TBL] [Abstract][Full Text] [Related]
14. Steric Repulsion Forces Contributed by PEGylation of Interleukin-1 Receptor Antagonist Reduce Gelation and Aggregation at the Silicone Oil-Water Interface.
Sorret LL; Monticello CR; DeWinter MA; Schwartz DK; Randolph TW
J Pharm Sci; 2019 Jan; 108(1):162-172. PubMed ID: 30395835
[TBL] [Abstract][Full Text] [Related]
15. Evaluating the autoinduction expression system and one-step purification for high-level expression and purification of gallbladder-derived rhIL-1Ra.
Bashir H; Ahmed N; Khan MA; Zafar AU; Tahir S; Kanwal H; Khan F; Rahman ZU; Husnain T
Biotechnol Appl Biochem; 2017 Jan; 64(1):20-26. PubMed ID: 26620912
[TBL] [Abstract][Full Text] [Related]
16. Nanoparticle Tracking Analysis to Examine the Temperature-Induced Aggregation of Proteins.
Sladek S; McComiskey K; Healy AM; Tajber L
Methods Mol Biol; 2019; 2039():131-139. PubMed ID: 31342424
[TBL] [Abstract][Full Text] [Related]
17. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group.
Fisher CJ; Dhainaut JF; Opal SM; Pribble JP; Balk RA; Slotman GJ; Iberti TJ; Rackow EC; Shapiro MJ; Greenman RL
JAMA; 1994 Jun; 271(23):1836-43. PubMed ID: 8196140
[TBL] [Abstract][Full Text] [Related]
18. Interference from Proteins and Surfactants on Particle Size Distributions Measured by Nanoparticle Tracking Analysis (NTA).
Bai K; Barnett GV; Kar SR; Das TK
Pharm Res; 2017 Apr; 34(4):800-808. PubMed ID: 28155075
[TBL] [Abstract][Full Text] [Related]
19. Recombinant human interleukin-1 receptor antagonist reduces acute lethal toxicity and protects hematopoiesis from chemotoxicity in vivo.
Qian L; Xiang D; Zhang J; Zhu S; Gao J; Wang X; Gao J; Zhang Y; Shen J; Yu Y; Han W; Wu M
Biomed Pharmacother; 2013 Mar; 67(2):108-15. PubMed ID: 23433850
[TBL] [Abstract][Full Text] [Related]
20. Nanoparticle-nanobubble interactions: Charge inversion and re-entrant condensation of amidine latex nanoparticles driven by bulk nanobubbles.
Zhang M; Seddon JRT; Lemay SG
J Colloid Interface Sci; 2019 Mar; 538():605-610. PubMed ID: 30553093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
